null Skip to main content
Sign in

PNC-28

PNC-28 (5mg), Limitless Biotech
$159.99

Bulk discount rates

  • -5% (buy 5~9)
  • -10% (buy 10~14)
  • -15% (buy 15+)

✓ Third-party tested by certified labs

✓ Published certificates of analysis

✓ 99% purity standard

Synthetic p53-penetratin peptide analog for HDM-2 binding research and pancreatic cancer cell membrane interaction studies.

Product Description

PNC-28 is a synthetic 27-amino-acid chimeric peptide containing a shorter HDM-2 binding domain derived from p53 tumor suppressor protein (residues 17-26) fused to the same cell-penetrating peptide (CPP) sequence used in PNC-27. This membrane-active peptide represents a truncated analog that lacks the first five amino acids of PNC-27's p53 domain while retaining selective cytotoxic activity against cancer cells.

Research investigations have examined PNC-28 in studies of HDM-2/p53 protein interactions, pancreatic cancer cell necrosis mechanisms, transmembrane pore formation, and penetratin-mediated cell entry pathways. The compound is used in controlled laboratory environments for investigating anticancer peptide structure-activity relationships, membrane disruption mechanisms, and selective tumor cell targeting in various cancer cell lines including pancreatic, ovarian, and breast cancer models. 

Supplied as pharmaceutical-grade lyophilized powder with third-party verified purity testing for qualified research institutions conducting in vitro research applications only.

Our Product Quality Guarantee

Every Limitless Biotech compound undergoes independent testing for endotoxins and sterility, meeting rigorous research standards through our systematic quality protocols and proactive manufacturing processes.

Buy PNC-28 Peptide From Limitless Biotech

Limitless Biotech provides USA-manufactured PNC-28 peptide for sale with verified molecular sequences and purity through comprehensive third-party testing. We ensure research quality with same-day shipping and dedicated customer support for your scientific endeavors.

Recently Viewed

loading

 

 
loading

 

 
loading

 

 
loading